Leerink Partnrs Has Positive Outlook of Cencora Q1 Earnings

Cencora, Inc. (NYSE:COR) – Leerink Partnrs upped their Q1 2025 earnings estimates for Cencora in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $3.45 per share for the quarter, up from their previous forecast of $3.43. The consensus estimate for Cencora’s current full-year earnings is $13.64 per share. Leerink Partnrs also issued estimates for Cencora’s Q2 2025 earnings at $4.12 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.99 EPS, FY2027 earnings at $18.91 EPS and FY2028 earnings at $20.72 EPS.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.21 by $0.13. The company had revenue of $79.05 billion for the quarter, compared to analysts’ expectations of $77.68 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%.

A number of other brokerages have also recently weighed in on COR. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday. Leerink Partners cut their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Bank of America reaffirmed a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Trading Up 0.3 %

Shares of NYSE COR opened at $248.42 on Friday. The company’s fifty day moving average is $231.95 and its 200-day moving average is $230.84. The stock has a market cap of $48.95 billion, a price-to-earnings ratio of 33.08, a P/E/G ratio of 1.49 and a beta of 0.44. Cencora has a twelve month low of $191.11 and a twelve month high of $251.00. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s payout ratio is currently 29.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Lake Street Advisors Group LLC grew its stake in Cencora by 1.3% in the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock valued at $769,000 after buying an additional 43 shares during the last quarter. Financial Advocates Investment Management grew its stake in Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after buying an additional 44 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in Cencora by 1.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after purchasing an additional 46 shares during the period. Prime Capital Investment Advisors LLC boosted its holdings in Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after purchasing an additional 46 shares during the period. Finally, Checchi Capital Advisers LLC boosted its holdings in Cencora by 2.2% in the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock valued at $499,000 after purchasing an additional 48 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.